Trial Profile

Olaparib Dose Escalation Trial in Patients Treated With Radiotherapy for Stage II-III Laryngeal and Stage II-III HPV-negative Oropharyngeal Squamous Cell Carcinoma

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 08 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Olaparib (Primary)
Indications Head and neck cancer; Laryngeal cancer; Oropharyngeal cancer; Squamous cell cancer
Focus Adverse reactions

Most Recent Events

24 Oct 2023 Results assessing the maximum tolerated dose (MTD) of the PARP inhibitor olaparib in combination with radiotherapy in patients with head and neck squamous cell carcinoma presented at the 48th European Society for Medical Oncology Congress
27 Sep 2022 Planned End Date changed from 1 Jan 2022 to 1 Jan 2024.
03 Aug 2021 Planned End Date changed from 1 Apr 2021 to 1 Jan 2022.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com